Literature DB >> 15756530

[Long-acting methylphenidate. An alternative medical therapy for adult patients with attention deficit hyperactivity disorder].

E Sobanski1, B Alm.   

Abstract

We report a 44-year-old female patient with attention deficit hyperactivity disorder (ADHD), combined subtype (DSM-IV: 314.01), who was treated with 0.5 mg of short-acting immediate-release methylphenidate/kg body weight given t.i.d. (total daily MPH IR dosage 45 mg). Under this medication, the patient reported significant reduction of symptoms. However, several times a day she experienced severe rebound phenomena with pronounced concentration disturbances, unrest, and dysphoric mood. After changing the medication to long-acting methylphenidate once daily (total daily OROS MPH dosage 54 mg), the rebound phenomena stopped, with equivalent beneficial clinical effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15756530     DOI: 10.1007/s00115-005-1892-y

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  9 in total

Review 1.  [ADHD in adulthood--guidelines based on expert consensus with DGPPN support].

Authors:  D Ebert; J Krause; C Roth-Sackenheim
Journal:  Nervenarzt       Date:  2003-10       Impact factor: 1.214

2.  Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder.

Authors:  T E Wilens; J Biederman; T J Spencer; J Frazier; J Prince; J Bostic; M Rater; J Soriano; M Hatch; M Sienna; R B Millstein; A Abrantes
Journal:  J Clin Psychopharmacol       Date:  1999-06       Impact factor: 3.153

3.  Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder.

Authors:  T Spencer; J Biederman; T Wilens; S Faraone; J Prince; K Gerard; R Doyle; A Parekh; J Kagan; S K Bearman
Journal:  Arch Gen Psychiatry       Date:  2001-08

Review 4.  Clinical suggestions for management of stimulant treatment in adolescents.

Authors:  M Weiss; U Jain; J Garland
Journal:  Can J Psychiatry       Date:  2000-10       Impact factor: 4.356

5.  A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder.

Authors:  R Paterson; C Douglas; J Hallmayer; M Hagan; Z Krupenia
Journal:  Aust N Z J Psychiatry       Date:  1999-08       Impact factor: 5.744

6.  Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder.

Authors:  M L Wolraich; L L Greenhill; W Pelham; J Swanson; T Wilens; D Palumbo; M Atkins; K McBurnett; O Bukstein; G August
Journal:  Pediatrics       Date:  2001-10       Impact factor: 7.124

7.  [Reliability and validity of the Wender-Utah-Rating-Scale short form. Retrospective assessment of symptoms for attention deficit/hyperactivity disorder].

Authors:  P Retz-Junginger; W Retz; D Blocher; R-D Stieglitz; T Georg; T Supprian; P H Wender; M Rösler
Journal:  Nervenarzt       Date:  2003-11       Impact factor: 1.214

8.  Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: a pilot study.

Authors:  Daniel J Cox; R Lawrence Merkel; Jennifer Kim Penberthy; Boris Kovatchev; Cheryl S Hankin
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2004-03       Impact factor: 8.829

9.  A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder.

Authors:  T Spencer; T Wilens; J Biederman; S V Faraone; J S Ablon; K Lapey
Journal:  Arch Gen Psychiatry       Date:  1995-06
  9 in total
  1 in total

Review 1.  Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants.

Authors:  Jan Buitelaar; Rossella Medori
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-10-13       Impact factor: 4.785

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.